PCSK9 and diabetes mellitus: Whichever the underlying mechanisms, our findings of a putative selective effect of PCSK9 on EPC number only in patients with diabetes may provide a mechanistic explanation for the results of the ODYSSEY OUTCOMES trial, a randomised, double-blind, placebo-controlled trial performed in patients on high-intensity statin-treatment, showing that the anti-PCSK9 antibody alirocumab produced about twice the absolute reduction in CV events among patients with diabetes as in those without diabetes54.